Angiotensin II for Refractory Shock: A Third Way to Raise Blood Pressure

The clinical scenario

In distributive (vasodilatory) shock — most often septic shock — the blood vessels dilate pathologically and blood pressure collapses despite adequate fluids. The mainstay is the vasopressor norepinephrine, often with vasopressin added. But some patients stay dangerously hypotensive on high doses. Angiotensin II (Giapreza) offers a third, independent way to raise blood pressure. This use case explains its role; it is used only in intensive care by clinicians managing shock.

Why the mechanism fits

The key idea in refractory shock is combining mechanisms rather than pushing one drug to its limit. Each vasopressor acts through a different receptor system:

• Norepinephrine → adrenergic receptors
• Vasopressin → V1 receptors
• Angiotensin II → AT1 receptors of the renin-angiotensin system

Synthetic angiotensin II is identical to the body's own most potent vasoconstrictor peptide. Binding AT1 receptors on vascular smooth muscle triggers powerful constriction of arteries and veins, raising systemic vascular resistance and blood pressure through a pathway the other agents don't touch. (For the full system — and the striking fact that this same peptide is blocked by ACE inhibitors and ARBs in chronic disease — see the renin-angiotensin system.)

What the evidence showed

In its pivotal randomized trial, ATHOS-3, adding angiotensin II to patients with catecholamine-resistant vasodilatory shock significantly improved the blood-pressure response compared with placebo — letting the target mean arterial pressure be reached more often, and allowing standard vasopressor doses to be reduced. This established it as an option when conventional vasopressors are not enough.

How it is used

Angiotensin II is delivered as a continuously titrated intravenous infusion (a central line is preferred), because its half-life is under a minute. Clinicians start low and adjust frequently to a blood-pressure target, weaning as the patient improves, with continuous hemodynamic monitoring.

The main safety consideration

As a powerful vasoconstrictor, angiotensin II carries a recognized risk of blood clots (arterial and venous thromboembolism), so guidelines recommend venous thromboprophylaxis during use. It does not treat the cause of shock — for sepsis that means antibiotics, source control, and organ support — but it helps keep organs perfused while the underlying problem is treated.

> This use case is educational and not medical advice. Angiotensin II is an intensive-care medicine used by clinicians experienced in managing shock.